Dr. Braden Manns
Co-Chair
Scientific Advisory Group
Alberta Health Services

Hydroxychloroquine

Scientific Advisory Group COVID-19 Recommendations
novel coronavirus (COVID-19)

AHS’ Scientific Advisory Group is connecting with clinicians, operational leaders, researchers and other experts to review emerging evidence and guidance of national and international bodies to provide information for focused areas of healthcare in relation to COVID-19. These resources are created to provide research informed advice to AHS physicians, staff, patients and families. Reports are updated frequently based on emerging evidence or concerns.

COVID-19 Resources for AHS Staff & Health Professionals

Key Research Question:
What is the evidence for and risks of using hydroxychloroquine (HQ) as a treatment and prophylaxis for SARS-CoV-2? [Updated April 16, 2019]

www.albertahealthservices.ca

April 20, 2020

Key Messages from the Evidence Summary

• Evidence for HQ effectiveness in treated COVID-19 is limited
  • Plausible in vitro activity
  • Equivocal in vivo data (observational studies, small RCTs)
• No evidence for HQ use as prophylaxis
  • RCTs are underway in HCWs and close contacts
• HQ risks include serious clinical and lab adverse effects
  • Especially in patients with cardiopulmonary compromise
  • Potential drug-drug interactions
  • Risk to children if unintentional ingestion

April 20, 2020

This material is for individual use only and not to be used for further dissemination.
For more information visit


- Alberta HOPE COVID-19 Trial: [https://www.hopecovid.ca/COVID-19](https://www.hopecovid.ca/COVID-19)

- COVID-19 PEP RCT: [https://www.covid-19research.ca/](https://www.covid-19research.ca/)